Tag - CLVS

Developments

Clovis enrolls first patient in Phase 2 portion of gynecologic cancer trial

Clovis Oncology (NASDAQ:CLVS) enrolled the first patient in the Phase 2 portion of its LIO-1 trial evaluating lucitanib for the treatment of gynecologic cancers. The trial is designed to evaluate the safety and efficacy...

August 6, 2020

Markets

SVB Leerink cuts Clovis Oncology to underperform; PT to $5 from $10

SVB Leerink downgraded Clovis Oncology (NASDAQ:CLVS) to “underperform” from “market perform” and halved its price target to $5 from $10, citing a fading opportunity in prostate cancer and escalating cash constraints...

April 27, 2020

Tag - CLVS

Clovis enrolls first patient in Phase 2 portion of gynecologic cancer trial

SVB Leerink cuts Clovis Oncology to underperform; PT to $5 from $10

General

More